Back

OMECARDIO trial: a randomized, double-blind, placebo-controlled study on the impact of omega-3 on inflammageing biomarkers and vascular stiffness in hypertensive and dyslipidemic patients

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Inflammation, immunity, and fibrosis Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Sebastian Eduardo Obregon

Austral University Hospital, Pilar (Argentina)

5 More presentations in this session

Presentation thumbnail
Associations of gingival inflammation with blood pressure among community-dwelling older women and men with periodontitis
Doctor E. Kringeland (Bergen, NO)
Abstract Slides Video
Presentation thumbnail
Quercetin blocks senescence-related cardiorenal fibrosis induced by hypertension
Miss N. Xiong (Nanjing, CN)
Abstract Slides Video
Presentation thumbnail
Tgfb increases platelet PAR4 expression to exacerbate thrombotic risk in hypertension
Doctor M. Wang (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Correlation study of systemic inflammatory response with aldosterone: a comparison between essential hypertension and primary aldosteronism
Professor C. Liu (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Features of changes in the blood levels of pro-inflammatory interleukin-17A in patients with arterial hypertension, which occurs with a background of abdominal obesity
Professor S. Koval (Kharkiv, UA)
Abstract Slides Video

Access the full session

Session thumbnail
Inflammation, immunity, and fibrosis

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Associations of omega-3 fatty acid subclasses with cardiovascular diseases in 500,000 individuals
thumbnail
Congress Presentation
High serum EPA and DHA levels are inversely associated with cardiovascular mortality in different arterial territories
thumbnail
Congress Presentation
Metabolic signature of prevalent cardiovascular diseases

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources